Gemini priming attenuates inflammation in human peripheral blood mononuclear cells
Revelation Biosciences to host Fireside Chat at 37th Annual Roth Conference
Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2024
Revelation Biosciences doses first patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients
Revelation Biosciences, Inc. Receives Continued NASDAQ Listing Approval
Revelation Biosciences Inc. Announces 1-for-16 Reverse Stock Split effective January 28, 2025
Revelation Biosciences Starts its PRIME Phase 1b Clinical Study of Gemini in CKD Patients
Revelation Biosciences Inc. Reminds You to Vote for the Special Meeting on January 17, 2025
Nasdaq Grants Revelation Biosciences Inc. Continued Listing
Revelation Biosciences Inc. Announces Exercise of Warrants for $4 Million in Gross Proceeds
Revelation Biosciences Inc. Announces FDA Acceptance of Gemini IND
Revelation Biosciences, Inc. Completes the GMP Manufacture of Gemini Clinical Drug Supply
Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2024
Revelation Biosciences’ Gemini Induces Dose Dependent Significant Increases in IL-10
Revelation Biosciences Inc. Announces Exercise of Warrants for $3.8 Million in Gross Proceeds
Revelation Biosciences Announces Phase 1 Clinical Study of Gemini Met The Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity
Revelation Biosciences Has Completed Dosing of its First in Human Phase 1 Clinical Study of Gemini
Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2024
Revelation Biosciences Inc. Gives Oral Presentation at Advances in Critical Care Nephrology (AKI & CRRT 2024)
Revelation Biosciences Inc. to Participate in a Virtual Fireside Chat at the 36th Annual Roth Conference
